CD8A and cancer: Because the absence of CD103+ DCs in the TME may be a critical rate-limiting step for initiating endogenous CD8+ T cell responses against cancer,31 our results argue that CXCR4-A-armed virotherapy followed by FL treatment is effective in the expansion of intratumoral CD103+ DCs.